17-AAG

17-AAG is an inhibitor of heat shock protein 90 (Hsp90) and a derivative of geldanamycin (Item No. 13355) that selectively inhibits BT474 tumor cell Hsp90 over fibroblast Hsp90 (IC50s = 5 and 943 nM, respectively).{46058} It inhibits the growth of prostate cancer cell lines (IC50s = 25-45 nM) and promotes the degradation of HER2 and induces growth arrest and apoptosis in breast cancer cells overexpressing HER2 (IC50s = 4-72 nM).{20728,20725} In vivo, 17-AAG (25 mg/kg, i.p.) reduces tumor size in a G-415 gallbladder cancer mouse xenograft model.{46059}